Trial Profile
A 24-Week National, Multi-Centre, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Phase IIIb Study in India to Evaluate the Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jul 2020
Price :
$35
*
At a glance
- Drugs Saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 01 Sep 2016 Results of pooled analysis of this and eight other trials assessing efficacy and safety of sexagliptin published in the Diabetes Therapy (2016).
- 07 Apr 2011 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 07 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.